CpG寡核苷酸
核酸酶
CpG站点
寡核苷酸
Toll样受体9
TLR9型
磷酸二酯键
化学
外周血单个核细胞
分子生物学
先天免疫系统
G-四倍体
细胞生物学
生物
DNA甲基化
受体
生物化学
DNA
核糖核酸
基因
基因表达
体外
作者
Kazuaki Hoshi,Tomohiko Yamazaki,Yuuki Sugiyama,Kaori Tsukakoshi,Wakako Tsugawa,Koji Sode,Kazunori Ikebukuro
出处
期刊:Nucleic Acid Therapeutics
[Mary Ann Liebert]
日期:2019-03-05
卷期号:29 (4): 224-229
被引量:21
标识
DOI:10.1089/nat.2018.0761
摘要
Single-strand oligodeoxynucleotides (ODNs) containing unmethylated cytosine-phosphate-guanine (CpG) are recognized by the toll-like receptor 9, a component of the innate immunity. Therefore, they could act as immunotherapeutic agents. Chemically modified CpG ODNs containing a phosphorothioate backbone instead of phosphodiester (PD) were developed as immunotherapeutic agents resistant to nuclease degradation. However, they cause adverse side effects, and so there is a necessity to generate novel CpG ODNs. In the present study, we designed a nuclease-resistant nonmodified CpG ODN that forms G-quadruplex structures. G-quadruplex formation in CpG ODNs increased nuclease resistance and cellular uptake. The CpG ODNs designed in this study induced interleukin-6 production in a human B lymphocyte cell line and human peripheral blood mononuclear cells. These results indicate that G-quadruplex formation can be used to increase the immunostimulatory activity of CpG ODNs having a natural PD backbone.
科研通智能强力驱动
Strongly Powered by AbleSci AI